Siga Technologies INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31)
Siga Technologies INC (SIGA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31) of $700.00 thousand for the 12-month period ending 2012-12-31, per its 10-K/A filed 2013-05-15.
Discontinued › Notes › Compensation Related Costs
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue · last filed 2013-05-15
- Siga Technologies INC share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for fiscal 2012 was $700.00K, a 72.00% decline from fiscal 2011.
- Siga Technologies INC share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for fiscal 2011 was $2.50M, a 66.67% increase from fiscal 2010.
- Siga Technologies INC share-based compensation arrangement by share-based payment award, options, vested in period, fair value (deprecated 2013-01-31) for fiscal 2010 was $1.50M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (Deprecated 2013-01-31) 12 month |
|---|---|
| 2012-12-31 | $700.00K 10-K/A · filed 2013-05-15 |
| 2011-12-31 | $2.50M 10-K/A · filed 2013-05-15 |
| 2010-12-31 | $1.50M 10-K/A · filed 2013-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |